TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age equal to or greater than 18.~2. Type 1 or 2 diabetes mellitus.~3. Wagner Grade 2 wound for at least 4 weeks. A diagnosis of a Wagner Grade 2 wound necessitates a persistent wound of 4 weeks (5).~4. DoD Beneficiary.~Exclusion Criteria:~1. Impending/urgent amputation due to ongoing or exacerbated infection.~2. Severe depression.~3. Claustrophobia.~4. Seizure disorder.~5. Uncontrolled asthma/severe COPD with pCO2 \> 45 mmHg on arterial blood gas.~6. Grade 4 congestive heart failure.~7. Unstable angina.~8. Chronic/acute otitis media/sinusitis.~9. Major tympanic membrane trauma.~10. Prior chemotherapy with Bleomycin and evidence of deterioration in diffusing capacity after a single hyperbaric oxygen exposure.~11. Candidates for vascular surgery/angioplasty/stenting or patients with major large vessel disease. These patients could have peripheral vascular disease of such severity that hyperbaric treatment would not improve their condition.~12. Vascular surgery/angioplasty within the last 3 months. This exclusion controls for improvements to a patients vasculature and perfusion that occur within 1-2 months after vascular surgery/angioplasty. This will ensure that any perfusion changes to the patient's diabetic wound ulcer area recorded during the study are a result of hyperbaric therapy instead of recent vascular procedures.~13. Women who are breast feeding or of childbearing potential.~14. Dementia or mental disability rendering the potential subject incapable of following instructions or consenting to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment plus Hyperbaric Oxygen (Type: EXPERIMENTAL): The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
- Standard treatment with Hyperbaric Room Air (Type: PLACEBO_COMPARATOR): The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Beta-hCG Test Reference Range Determination

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Apparently healthy, non-pregnant females, of any race.~2. \>18 years of age.~3. Willing to voluntarily agree to sign a consent form.~Exclusion Criteria:~1. Current pregnancy, suspected pregnancy, or pregnancy within previous 12 months.~2. Currently lactating/nursing a child.~3. Current diagnosis of Gestational Trophoblastic Disease, Gestational Trophoblastic Tumor or Gestational Trophoblastic Neoplasia.~4. Current diagnosis of non-trophoblastic tumors.~5. Current diagnosis of cancer and/or has undergone immunotherapy in the previous 12 months.~6. Current diagnosis of a serious health condition that involves inpatient care or continuing treatment by a health care provider, such as:~   * Conditions or treatments that result in continuous or episodic incapacity (e.g. pneumonia, epilepsy).~  * Permanent or long-term conditions (e.g. HIV, Alzheimer's, severe stroke).~  * Conditions requiring multiple treatment/recovery cycles (e.g. kidney disease).~7. Hospitalization (for \>24 hours) or major surgery within previous 3 months.~8. Unable, or unwilling, to provide required blood sample for testing.~9. Investigator believes subject is unsuitable for inclusion in the trial (i.e. has serious condition(s) or other reason(s) that could limit their ability to participate in the study; or impact the scientific integrity of the study).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years and older~* Biopsy-proved cervical cancer or endometrial cancer within three months of study enrollment~* Standard-of-care (SOC) FDG PET/CT exam performed within 30 days of study enrollment~Exclusion Criteria:~* Female \< 18 years old~* No history of cervical cancer or endometrial cancer~* Primary biopsy \> 3 months of study enrollment~* Systemic therapy or radiation therapy initiated~* SOC FDG PET/CT exam performed \> 30 days of study enrollment~* Therapeutic procedures (chemotherapy, radiation therapy) have been initiated~* Pregnancy or lactation~* Claustrophobia or inability to tolerate the imaging procedure on the PET/MR scanner~* Individual is not willing to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F fluciclovine PET scan (Type: EXPERIMENTAL): Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed and objectively confirmed acute venous thromboembolism~* Active malignancy~* Life expectancy of at least 6 months~* Performance-Status according to Karnofsky Performance Scale ≥ 70 %~* Patient's compliance and geographical situation allowing an adequate follow up~* platelets ≥ 100.000 /μl, INR \< 1.5, PTT \< 40 sec.~* written informed consent of the patient prior to any procedure in connection with the study~* male and female patients with an age of at least 18 years~Exclusion Criteria:~* therapeutic anticoagulation \> 96 hours prior to study treatment~* known allergic reactions against the study drugs or the substances included therein~* known conditions associated with high risk of bleeding, known history of hemorrhagic diathesis~* acute clinically relevant bleeding in the last 2 weeks~* any history of spontaneous major/cerebral bleeding~* history of heparin induced thrombocytopenia II~* pregnant or breast-feeding women. Women of child-bearing potential must have a negative pregnancy test performed \< 7 days prior to start of the treatment~* severe renal insufficiency (GFR \< 30 ml/min)~* liver disease with coagulation impairment, including Child B and C~* cirrhosis~* acute medical illness~* treatment of the underlying cancer with experimental therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Arm A: Rivaroxaban
- low-molecular heparine (Type: ACTIVE_COMPARATOR): Arm B: standard treatment with low-molecular heparine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Being scheduled to have elective primary minimally invasive 1 or 2 level transforaminal lumbar laminectomy interbody fusion~* ASA I, II, or III~* Informed consent form signed~Exclusion Criteria:~* Anyone weighing less than 50kg (as this would require a dosing change).~* Hypersensitivity or contraindication to intravenous acetaminophen or opioids~* Allergy to Methocarbamol; morphine sulfate, sevoflourane, or fentanyl~* Impairment of liver function-- defined as the inability to receive intravenous acetaminophen without dose adjustment as determined by the investigator; or history of chronic liver disease defined as history of hepatitis of any kind as recorded in the patient's chart~* Mental retardation recorded as a diagnosis in the patient's chart~* History of chronic pain (defined as currently receiving treatment from a specialist for pain)~* History of pain recalcitrant to intravenous morphine~* Impaired kidney function (defined as creatinine \> 1.5)~* Anyone who is not a candidate for general anesthesia or any other portion of the investigator's standard of

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- acetaminophen (Type: ACTIVE_COMPARATOR): 1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
- PlaceboComparator (Type: PLACEBO_COMPARATOR): Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Stiffening Wire in Colonoscopy With Pre-Owned Colonoscopes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years and older having screening or diagnostic colonoscopy~Exclusion Criteria:~* Previous hysterectomy~* Previous radical prostatectomy~* Clinical presentation or imaging study suggesting presence of lesion that could obstruct passage of colonoscope

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stiffening wire only if difficulty (Type: EXPERIMENTAL): Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
- Stiffening wire #1 transverse colon (Type: EXPERIMENTAL): Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
- Stiffening wire #2 transverse colon (Type: EXPERIMENTAL): Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cancer Nurse Navigators on Patient Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (18 years of age or older)~2. Treated at Aurora St. Luke's or West Allis Medical Center~3. New or recurrent dx of lung, prostate, colorectal or breast cancer -~Exclusion Criteria:~1. Previously received CNN services at an Aurora treatment facility~2. Unable to read/write in English~3. Living in a nursing home/long term care facility~4. Not capable of completing study questionnaires -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Nurse Navigator Services (Type: NO_INTERVENTION): None
- Services from a Nurse Navigator (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute Psychotic symptoms in Schizophrenia~* Schizoaffective disorder and Schizophreniform disorders in patients that required an admission into a hospital and in which physicians considered the use of risperidone as treatment under clinical practice~Exclusion Criteria:~* Pregnant or lactating patients~* Patients with psychiatry pathology other than Schizophrenia or schizoaffective disorder~* Patients with neurology pathology except Parkinsonism induced by neuroleptics~* Patients with other severe concomitant pathology~* Patients treated with risperidone in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: None): Risperidone as prescribed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals between the ages of 18-60~2. Meets DSM-5 criteria of current opioid use disorder with six consecutive months of reported heroin use, supported by a positive urine for opiates indicating regular use of heroin~3. Seeking treatment for opioid use disorder with Vivitrol~4. Capable of giving informed consent and complying with study procedures~5. In otherwise good health based on complete medical history and physical examination, laboratory tests, and EKG~6. BMI between 18-40~Exclusion Criteria:~1. Reported treatment with methadone in the last 3 months or positive urine toxicology for methadone on the day of consent~2. Maintenance on, or regular use of buprenorphine or other prescription opioids~3. Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.~4. Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT \> 3 times normal, AIDS (CD4 count under 200 currently or medically ill with an opportunistic infection), unstable diabetes, cardiovascular disease.~5. Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder, severe Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within the past year.~6. Physiologically dependent on alcohol or sedative- hypnotics with impending withdrawal. Other substance use diagnoses are not exclusionary.~7. History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.~8. Chronic neurocognitive disorder~9. History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.~10. Painful medical condition that requires ongoing opioid analgesia or anticipated surgery necessitating opioid medications~11. Fentanyl only use, supported by a urine toxicology that is positive for fentanyl only and negative for all other opioids.~12. Court mandated to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Short-term treatment with buprenorphine (Type: EXPERIMENTAL): Short-term treatment with buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fractional Laser Assisted Topical Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acne scars or traumatic scars scheduled for treatment with the fractional carbon dioxide laser~* Age ≥18 years~* Patient is willing and able to give written informed consent~Exclusion Criteria:~* Known allergy to local anesthesia~* Pregnancy or lactation~* Incompetency to understand what the procedure involves~* Current complaints of chronic pain or other alterations in pain sensation (e.g. due to diabetes mellitus or lepra)~* Current treatment with systemic analgesics or other medication that can influence pain sensation~* Total lesional area to be treated in one session \>600 cm2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Region 1 (Type: ACTIVE_COMPARATOR): Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
- Region 2 (Type: EXPERIMENTAL): Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Statin in Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years old or older.~* fracture of the femoral neck or of the trochanteric mass~* undergoing surgery within 5 days for this fracture~* Signed written informed consent~Exclusion Criteria:~* contraindication to rosuvastatin:~* active liver disease including unexplained and prolonged elevations of serum transaminases and any increase of serum transaminases beyond 3 times the upper limit of normal~* severe renal impairment (creatinine clearance calculated by the formula MDRD \<30 ml / min)~* myopathy~* use of cyclosporine~* statin therapy ongoing at the admission for fracture~* curative anticoagulant therapy ongoing at the admission and expected to be maintained after the intervention~* Patients considered by the investigator to be unable to participate to the study~* Refuse to participate

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 12 months of follow-up~* Patient initiating chronic dialysis (incident cases)~* Patients with a 3 year prognostic mortality score less than (\<) 10 points (Dusseux et al. 2015)~Exclusion Criteria:~* The patient is participating in another interventional study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* Patient on preemptive kidney transplant waiting list (before the initiation of a chronic dialysis program)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Chronic dialysis patients (Type: EXPERIMENTAL): The study population consists of patients over 70 (≥) and under 85 years (\<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (\<) 7 points (Dusseux et al. 2015).~Intervention: Systematic use of a prognostic score

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues